Physician profile
John Sherret
NPI 1699330381
$6,279.45
in general payments reported to CMS, 2019-2025
19 companies · $5,958 in 2025
The $5,958 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.88 · 2024: $302 · 2025: $5,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,100 · Food and Beverage: $1,259 · Travel and Lodging: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,099.99 |
| Food and Beverage | $1,258.80 |
| Travel and Lodging | $770.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,787.08 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $316.77 | 2024-2025 | Airsupra, Breztri, Fasenra |
| United Therapeutics Corporation | $194.84 | 2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $142.18 | 2025 | |
| Viatris Specialty LLC | $92.75 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $92.37 | 2025 | Winrevair, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.92 | 2025 | Ofev, Jascayd |
| Insmed, INC. | $80.39 | 2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $75.42 | 2025 | Dupixent |
| Grifols USA, LLC | $47.94 | 2025 | Prolastin-C Liquid |
| La Jolla Pharmaceutical Company | $38.81 | 2025 | Zevtera, Giapreza |
| Verona Pharma, INC. | $37.03 | 2025 | Ohtuvayre |
| Amgen INC. | $25.55 | 2024 | Tavneos |
| Daiichi Sankyo INC. | $23.71 | 2025 | Injectafer |
| Pfizer INC. | $20.31 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $19.01 | 2025 | |
| Alnylam Pharmaceuticals INC. | $17.78 | 2025 | Onpattro |
| Genzyme Corporation | $15.88 | 2025 | |
| Glaxosmithkline, LLC. | $15.14 | 2025 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sherret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.